MicroRNA-124 links p53 to the NF-κB pathway in B-cell lymphomas

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• The role of microRNAs (miRNAs) in lymphoma pathogenesis is not fully elucidated.
• The specific contribution of miRNA dysregulation to aggressive B-cell lymphomas coexpressing MYC and BCL2 remains unknown.

Purpose of the Study:

• To investigate the role of microRNA-124 (miR-124) as a regulator of MYC and BCL2 in B-cell lymphomas.
• To elucidate the molecular mechanisms underlying miR-124's function and its relationship with oncogenic and tumor-suppressive pathways.

Main Methods:

• Identification of miR-124 as a regulator of MYC and BCL2 expression.
• Assessment of miR-124's impact on lymphoma cell proliferation and survival.
• Mechanistic studies involving direct targeting of nuclear factor-κB (NF-κB) p65 by miR-124.
• Analysis of the miR-124 promoter region for functional p53 binding sites.
• Evaluation of p53's effect on miR-124, p65, MYC, and BCL2 expression.

Main Results:

• miR-124 acts as a negative regulator of MYC and BCL2 in B-cell lymphomas.
• Ectopic expression of miR-124 suppresses lymphoma cell proliferation and survival; inhibition enhances tumor fitness.
• miR-124 directly targets NF-κB p65, mediating the suppression of MYC and BCL2.
• A functional p53 binding site in the miR-124 promoter was identified.
• Wild-type p53 expression increases miR-124 levels and suppresses p65, MYC, and BCL2.

Conclusions:

• miR-124 is a key tumor suppressor in B-cell lymphomas, regulating MYC and BCL2 through the NF-κB pathway.
• The p53-miR-124-NF-κB axis represents a critical regulatory circuit in lymphoma.
• Disruption of this miRNA-dependent pathway is linked to MYC/BCL2 coexpression and poor prognosis in B-cell lymphoma.